Nanjing IASO Biotechnology Co., Ltd.

Works in Cardiovascular · Dermatology · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Women's health

Nanjing IASO Biotechnology Co., Ltd. is a clinical trial sponsor. It has 10 active clinical trials with 2,069 planned participants, across 8 therapeutic areas.

Trial track record · since 2021

10Active trials2,069 planned participants
0Completed0 with results posted
0Stopped earlyterminated, withdrawn or suspended

Pipeline · 10 active trials

StageTrialStatus

Questions about Nanjing IASO Biotechnology Co., Ltd

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.

Approve Suite is not affiliated with Nanjing IASO Biotechnology Co., Ltd..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.